HER2+ advanced breast cancer (monarcHER): a randomized, open-label, phase II trial. Ann Oncol. 2022;33(suppl 7):S1386–S1387. doi: 10.1016/j.annonc.2022.08.013.
Asaoka M, Narui K, Suganuma N, et al. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy. Eur J Surg Oncol. 2019;45(12):2289-2294. Ferraro ...
Jung KH, Gong G, Kim HH, Lee S, Lee J, Kim SB. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy. Eur J Cancer. 2022;176:30–40.
After 10 years approximately 40% of patients will have experienced a recurrence. From previous data in HER2-untested cohorts [7-9,11,12], reporting that HR expression exhibits time-dependent nonproportional hazard effects on prognosis [8,9], it was unclear whether these effects would also be ...
22.Mittendorf EA, Lu B, Melisko M, Price Hiller J, Bondarenko I, Brunt AM, et al. Efficacy and safety analysis of Nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin Cancer Res. 2019;25(14):4248–54. ...
Recurrence Free Survival (RFS) was 35 months for HER2+ and 43 months for HER2 loss (P = 0.007). However, short follow-up time since diagnosis likely contributed to the underrepresentation of the true RFS of both groups. Therefore, at our institution, retained HER2 positivity on RD after ...
cells (BCSCs) have unfavorable clinical outcomes. MicroRNAs (miRNAs) regulate key features of BCSCs. We hypothesized that a biology-driven model based on BCSC-associated miRNAs could predict prognosis for the most common subtype, hormone receptor (HR)-positive, HER2-negative breast cancer patients....
frequent recurrence pattern in the HER-2 negative luminal type breast cancer patients, especially, in the double hormone receptor-positive patients who received non-standardized hormone therapy. The prognosis for patients with late recurrence is better than that in the patients with early recurrence. ...
[8] Horisawa N, Adachi Y, Takatsuka D, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Bre...
human breast cancers2,3 and have been shown to be associated with poorer prognosis on multi- variate analyses.4,5 In an effort to improve the outcomes of patients with HER2 positive (HER2+) breast cancer, research has focused on developing therapies directed to the HER2 receptor and its ...